Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 3810

BillFederalHouseIn Committee
To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.
About This Bill
Committee
Latest Action · June 9, 2023
Referred to the Subcommittee on Health.
Congress
118th (2023–2025)
Introduced
June 5, 2023
Cosponsors (4)
4D 0R
View PDF ↗

Summary

Highlight any text to annotate
Drug Origin Transparency Act of 2023 This bill requires drug manufacturers to report on the suppliers of ingredients used in their products. Specifically, drug manufacturers must report information relating to the supply chain of their products, including the suppliers of active ingredients and the amount of drugs that are manufactured using those ingredients. Drug manufacturers must also include information about the manufacturers of ingredients on the labels of their products.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.